Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases

Bagán, José; Murillo, Judith; Jiménez, Yolanda; Poveda, Rafael; Milián, ML; Sanchis, José M.; Silvestre, Francisco-Javier; Scully, Crispian

doi:10.1111/j.1600-0714.2004.00269.x

Cited by 223 publications

(155 citation statements)

References 16 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…4 Osteonecrosis of the jaw (ONJ) has become a major concern for cancer patients taking these drugs. [5][6][7][8][9][10] Although an abundance of case series have been published on this topic since 2003, there is currently inadequate scientific evidence through well controlled epidemiologic studies that explore the association between exposure and disease.…”

Section: Introductionmentioning

confidence: 99%

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

Wessel

Dodson

Zavras

2008

Journal of Oral and Maxillofacial Surgery

175

121

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

Wessel

Dodson

Zavras

2008

Journal of Oral and Maxillofacial Surgery

175

121

View full text Add to dashboard Cite

show abstract

“…Likewise, patients were excluded if they presented any type of neoplasia, because of the possibility that bone metastasis could have occurred. 7 The use of corticoids and anti-convulsive 13 medications was also an exclusion criterion.…”

Section: Methods Subjectsmentioning

confidence: 99%

“…4 Thus, for dentists to be able to decide whether it is opportune to intervene surgically in relation to bone tissue, the degree of bone modeling occurring in maxillary bones needs to be known 5 . The greatest fear is osteonecrosis of the jaws, 6,7 particulary for those patients that have used bisphosphonates intravenously for treating metastatic cancer disease of bones such as breast cancer, multiple myeloma and prostatic cancer. It is in this respect that the use of biochemical markers for bone remodeling may contribute towards this analysis.…”

Section: Introductionmentioning

confidence: 99%

Use of the plasma CTX for assessing the bone activity of the mandible among osteopenic and osteoporotic patients

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to determine whether the plasma CTX bone remodeling marker is useful for indicating the bone metabolic activity level of the mandible. Thirty-six patients were selected; all were postmenopausal and aged 50 years or over. In accordance with the WHO criteria for osteoporosis, a control group was set up (n = 10) in which the T-score was greater than -1 and a diseased group with Tscore less than -1. Using MDP-99m Tc samples, the radioisotope uptake in the femoral neck (R 2 ) and mandibular body (R 1 ) was analyzed. A third examination was performed using the plasma CTX biochemical bonemodeling marker. The inferential results for the diseased group showed that Ln(R 1 ) presented a statistically significant linear relationship with Ln(CTx) (p = 0.067) and with the T-score (p = 0.018). The plasma CTX bone remodeling marker is useful for monitoring the bone metabolic activity of the mandible.

show abstract

“…La plupart de ces études rapportent des cas uniques ou des séries de cas relativement peu importantes dont les résultats sont totalement contradictoires. Selon les publications, on arrive à l'une des conclusions suivantes : -l'OHB a un effet bénéfique sur le traitement des ONM [2,7,22,28,32,37,[50][51][52][53][54][55] entrainant une diminution de la taille et du nombre de foyers d'ostéonécrose, et une cicatrisation plus rapide ; -aucune conclusion n'est possible [9,31,56,57] ; -l'OHB n'a aucun impact bénéfique sur les ONM [20,[58][59][60][61][62][63][64].…”

Section: Résultats De L'utilisation De L'ohb Dans Le Traitement Des Ounclassified

Intérêt de l’oxygénothérapie hyperbare dans la prévention et le traitement des ostéonécroses des maxillaires dues aux bisphosphonates

Gunepin

Derache

Cathelinaud

et al. 2013

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Résumé -Les bisphosphonates (BP) sont des inhibiteurs du remodelage osseux indiqués dans la prise en charge de pathologies malignes (myélome multiple, métastases de tumeurs solides, etc.) et bénignes (ostéoporose, maladie de Paget, etc.). Depuis 2003, un effet indésirable imputé à cette classe de médicaments est apparu dans la littérature : les ostéonécroses des maxillaires (ONM) induites par la prise de BP. Cliniquement, l'ONM se caractérise par une exposition d'os nécrotique qui persiste pendant plus de 8 semaines. En 2007, puis 2009, l'American Association of Oral and Maxillofacial Surgeons (AAOMS) a émis des recommandations destinées aux professionnels de santé pour prévenir et prendre en charge cet effet indésirable. Cependant, l'absence de thérapeutiques efficaces a poussé de nombreux auteurs à tester, en complément des thérapies proposées par l'AAOMS, des traitements expérimentaux au nombre desquels figure l'oxygénothérapie hyperbare (OHB). D'un point de vue théorique, l'étiopathogénie des ONM n'étant pas connue, l'impact de l'OHB sur les mécanismes de survenue de cette pathologie reste hypothétique. D'un point de vue clinique, les avis divergent sur l'intérêt de l'utilisation de l'OHB dans le traitement des ONM. Cependant, les résultats préliminaires de deux essais cliniques contrôlés et randomisés en cours aux Etats-Unis laissent à penser que l'OHB pourrait trouver de nouvelles indications en chirurgie orale dans le traitement mais aussi la prévention des ONM.Abstract -Interest of hyperbaric oxygen therapy in the prevention and treatment of bisphosphonate-related osteonecrosis of the jaws. Bisphosphonates (BP) have been used since 1960s for their capability to alter the mechanism of bone resorption and remodeling. Intravenous (IV) BP are effective in the treatment and management of cancer-related conditions including hypercalcemia of malignancy, skeletal-related events associated with bone metastases in the context of solid tumors such as breast cancer, prostate cancer and lung cancer, and management of lytic lesions in the setting of multiple myeloma. Oral BP are used to treat osteoporosis and osteopenia. In 2003, oral and maxillofacial surgeons first recognized and reported cases of non-healing exposed bone in the maxillofacial region in patients treated with IV bisphosphonates. This adverse effect was called BONJ for bisphosphonate-related osteonecrosis of the jaws. Clinically, BONJ is defined by an exposed bone in the maxillofacial region that has persisted for more than 8 weeks. So far, the etiopathogenesis of BONJ remains

show abstract

Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases

Abstract: ONJ appears to have a relationship with the use of bisphosphonates.

Cited by 223 publications

References 16 publications

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

Use of the plasma CTX for assessing the bone activity of the mandible among osteopenic and osteoporotic patients

Intérêt de l’oxygénothérapie hyperbare dans la prévention et le traitement des ostéonécroses des maxillaires dues aux bisphosphonates

Contact Info

Product

Resources

About